79 related articles for article (PubMed ID: 10938525)
1. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood.
Masquelier M; Vitols S; Pålsson M; Mårs U; Larsson BS; Peterson CO
J Drug Target; 2000; 8(3):155-64. PubMed ID: 10938525
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Masquelier M; Vitols S; Peterson C
Cancer Res; 1986 Aug; 46(8):3842-7. PubMed ID: 3731059
[TBL] [Abstract][Full Text] [Related]
3. Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells.
Vitols S; Gahrton G; Peterson C
Cancer Treat Rep; 1984 Mar; 68(3):515-20. PubMed ID: 6322988
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells.
Masquelier M; Lundberg B; Peterson C; Vitols S
Leuk Res; 2006 Feb; 30(2):136-44. PubMed ID: 16085310
[TBL] [Abstract][Full Text] [Related]
5. Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications.
Vitols S
Cancer Cells; 1991 Dec; 3(12):488-95. PubMed ID: 1840290
[TBL] [Abstract][Full Text] [Related]
6. [Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives].
Favre G
C R Seances Soc Biol Fil; 1992; 186(1-2):73-87. PubMed ID: 1450992
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel.
Seiter K; Feldman EJ; Traganos F; Li X; Halicka HD; Darzynkiewicz Z; Lederman CA; Romero MB; Ahmed T
Leukemia; 1995 Nov; 9(11):1961-6. PubMed ID: 7475290
[No Abstract] [Full Text] [Related]
8. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway.
Lundberg B
Cancer Res; 1987 Aug; 47(15):4105-8. PubMed ID: 3607752
[TBL] [Abstract][Full Text] [Related]
9. Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein.
de Smidt PC; van Berkel TJ
Cancer Res; 1990 Dec; 50(23):7476-82. PubMed ID: 2147578
[TBL] [Abstract][Full Text] [Related]
10. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Burger H; Nooter K; Zaman GJ; Sonneveld P; van Wingerden KE; Oostrum RG; Stoter G
Leukemia; 1994 Jun; 8(6):990-7. PubMed ID: 7911548
[TBL] [Abstract][Full Text] [Related]
11. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme.
Nikanjam M; Gibbs AR; Hunt CA; Budinger TF; Forte TM
J Control Release; 2007 Dec; 124(3):163-71. PubMed ID: 17964677
[TBL] [Abstract][Full Text] [Related]
12. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.
Vaidya B; Vyas SP
J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366
[TBL] [Abstract][Full Text] [Related]
13. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.
Vitols S; Angelin B; Ericsson S; Gahrton G; Juliusson G; Masquelier M; Paul C; Peterson C; Rudling M; Söderberg-Reid K
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2598-602. PubMed ID: 2320578
[TBL] [Abstract][Full Text] [Related]
14. [The spatial reorganization of the perinucleolar area of hematopoietic cells in human leukemias].
Levitan NV; Shorina GN; Degtiaeva MM; Loseva MI; Iakobson GS; Monakhova MA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1990; (11):128-37. PubMed ID: 1705827
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
16. [The cytotoxic effect of a low density lipoprotein delivered aclarubicin on leukemia cells].
Li W; Xi S; Zhang M
Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):636-8. PubMed ID: 16200711
[TBL] [Abstract][Full Text] [Related]
17. Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo.
Vitols S; Peterson C; Larsson O; Holm P; Aberg B
Cancer Res; 1992 Nov; 52(22):6244-7. PubMed ID: 1423268
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
19. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.
Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK
J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980
[TBL] [Abstract][Full Text] [Related]
20. Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics.
Letchford K; Burt HM
Mol Pharm; 2012 Feb; 9(2):248-60. PubMed ID: 22204437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
